Bcma Spain company information, Employees & Contact Information

BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells Nature

Cullinan pens $700M pact for BCMA bispecific to pair with another autoimmune T-cell engager Fierce Biotech

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy Nature

Your questions about BCMA and multiple myeloma, answered MD Anderson Cancer Center

Off-the-Shelf CAR-T Therapy P-BCMA-ALLO1 Shows Strong Activity in R/R Myeloma Targeted Oncology

BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions JCI.org

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy Frontiers

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting Journal of Hematology & Oncology

Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo Science | AAAS

BCMA-Directed Bispecific Antibodies for Multiple Myeloma: Practical Approaches to Patient Management Journal of Hematology Oncology Pharmacy

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms ScienceDirect.com

B cell maturation antigen (BCMA) is dispensable for the survival of long-lived plasma cells Nature

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma Nature

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches Nature

Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma | Blood Cancer Journal Nature

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation Nature

Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth Nature

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial Nature

Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody Nature

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results Nature

BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease The New England Journal of Medicine

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma | Blood Cancer Journal Nature

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma Nature

Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy Nature

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome Science | AAAS

What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D? The ASCO Post

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma Journal of Hematology & Oncology

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma Nature

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma Nature

Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma | Leukemia Nature

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma The New England Journal of Medicine

Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results Nature

ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets Fierce Biotech

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma Nature

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma Journal of Hematology & Oncology

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma Journal of Experimental & Clinical Cancer Research

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains Nature

Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients Nature

Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma | Leukemia Nature

Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market Fierce Biotech

Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts Fierce Pharma

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo Nature

γ-secretase directly sheds the survival receptor BCMA from plasma cells Nature

Pfizer halts BCMA trial amid safety woes, hit by DMD delay Fierce Biotech

GlaxoSmithKline jumps into myeloma with 'homemade' anti-BCMA drug Blenrep Fierce Pharma

AstraZeneca drops BCMA drug after seeing early clinical data Fierce Biotech

GSK's anti-BCMA drug hits goal in pivotal multiple myeloma test Fierce Biotech

Gilead drops anti-BCMA CAR-T from Kite, takes $820M charge Fierce Biotech

About | The BCMA The Branded Content Marketing Association